These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18565901)

  • 1. Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-stimulating Agent Guidelines.
    Murray N; Klasa R
    J Clin Oncol; 2008 Jun; 26(18):3096-7. PubMed ID: 18565901
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 3. Updated clinical practice guidelines on erythropoiesis-stimulating agents.
    Silver SM
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):945-6. PubMed ID: 18277954
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents: creation and validation of a computerized prescriber order entry alert.
    Ensor CR; Kockler DR; Dugger RW; Hylton-Gravatt LA
    Ann Pharmacother; 2009 Jun; 43(6):1143-4. PubMed ID: 19458108
    [No Abstract]   [Full Text] [Related]  

  • 6. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 8. Reevaluating erythropoiesis-stimulating agents.
    Cotter DJ
    N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin in cancer-related anemia.
    Fenner MH; Ganser A
    Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietins in oncology.
    Lattanzi SC
    N Engl J Med; 2007 Sep; 357(12):1262; author reply 1262-3. PubMed ID: 17881762
    [No Abstract]   [Full Text] [Related]  

  • 11. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology.
    Aapro M
    Oncologist; 2009; 14 Suppl 1():1-5. PubMed ID: 19762511
    [No Abstract]   [Full Text] [Related]  

  • 13. [Erythropoiesis-stimulating agents: favorable safety profile when used as indicated].
    Adam M
    Strahlenther Onkol; 2008 Sep; 184(9):490. PubMed ID: 19016030
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
    Katodritou E; Dimopoulos MA; Zervas K; Terpos E
    Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good practice guidelines on the use of erythropoiesis-stimulating agents in 2011.
    Pérez-Oliva Díaz JF
    Nefrologia; 2011; 31(3):361-2. PubMed ID: 21629342
    [No Abstract]   [Full Text] [Related]  

  • 17. Stabilizing hemoglobin levels: what's new in IV iron and anemia management?
    Fishbane S; Larson K; VanBuskirk S
    Nephrol Nurs J; 2008; 35(5):493-502. PubMed ID: 18856080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect for oncology of the national coverage determination for erythropoiesis-stimulating agents.
    Jorgenson JA
    Manag Care Interface; 2008 Jul; 21(1):7-8. PubMed ID: 18727312
    [No Abstract]   [Full Text] [Related]  

  • 20. Erythropoetic-stimulating agents: where do we stand?
    Dicato M
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii137-40. PubMed ID: 18790935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.